Form 4: Cytokinetics CEO Robert Blum Sells 25,000 Shares

Cytokinetics' CEO, Robert Blum, sold 25,000 shares of common stock at a price of $43.23 on March 5, 2025.

Summary

• On March 5, 2025, Robert I. Blum, the President and CEO of Cytokinetics Inc., sold 25,000 shares of the company's common stock.
• The sale was executed at a price of $43.23 per share.
• Following the transaction, Mr. Blum directly owns 381,151 shares of Cytokinetics Inc.
• Additionally, Mr. Blum indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it simply reports a transaction. The sale itself could be interpreted positively or negatively depending on the investor's perspective.

Negatives

• The CEO's sale of shares could be interpreted negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is not always the case.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sale.

Key Dates